{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/399045671"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics' forward-looking statements include, among others, our failure to successfully commercialize a new oral therapy for multiple sclerosis, the availability of additional financial and other resources, a failure of our clinical trial to achieve desired results, our failure to obtain FDA a" ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "bio-medicine.org" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/426472532"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/399045671"] } } }
